Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Edgewise Therapeutics (EWTX) announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, ...

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...

In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver ...

A routine blood test identified abnormalities, leading to follow-up tests. A hematologist diagnosed Evans with early-stage ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

BTK inhibitors work by blocking the BTK enzyme, which plays a role in B cell growth and proliferation. Pirtobrutinib is developed to overcome the tendency for cancer cells to become resistant to ...

Introduction Atrial fibrillation (AF) is the leading cause of cardioembolic stroke and is associated with increased stroke severity and fatality. Early identification of AF is essential for adequate ...

The results demonstrated that pirtobrutinib met its primary endpoint of non-inferiority on ORR against ibrutinib.

The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validates the safety and efficacy of a new drug, but also opens ...